Abstract:Introduction: Clot-based assays are employed to estimate coagulation factor activity in clinical pathology laboratories. These assays are PT- or aPTT-based and utilize dilutions of the patient's plasma in factor-deficient plasma. The curves of activity for each dilution follow a parallelism or non-parallelism pattern and the latter is typically seen in the presence of Lupus Anticoagulant (LA). Identification of this pattern is critical to avoid misdiagnosis of factor deficiency in patients who actually have an inhibitor. Materials and Methods: We observed low Factor XI (FXI) levels in patients with LA, while other factors were not affected. In order to determine the reason(s) why FXI levels are sensitive to LA, we collected 34 plasma samples from patients with dRVVT confirm ratio > 1.2, and estimated FVIII and FXI levels. FXI activity was also estimated with Dade ® Actin ® FS, a reagent that is not sensitive to the LA. The coefficient of variance (CV) for both FXI and FVIII levels were compared. To estimate the effects of heparin, plasma was spiked (0.1-1.0 IU/ML) and tested in the PTT, FXI, and FVIII assays. We tested with Dade ® Actin ® FS 4 known normal patients, 3 known FXI deficient patients, 20 known plasma positive for LA, and 10 with heparin. All assays were performed on a Siemens CS-5100 analyzer. Results: The results show that FXI is highly sensitive to LA, with non-parallelism and high CV, not observed with FVIII activity. As expected, FXI levels were not affected when LA-insensitive Dade ® Actin ® FS was used. Heparin (0.3-0.7 IU/ML) also showed non-parallelism in FXI activity, but not for FVIII. Only the highest dose of heparin (1.0 IU/ML) affected FVIII levels. Notably, the sensitivity of FXI activity to LA and heparin was explained by a few dilutions of the patient's plasma (5X) in the FXI assay, compared to other coagulation factors (20X). Of note, less diluted plasma is required for FXI activity because relatively higher levels of FXI is required to sustain and produce clot in the FXI-deficient plasma. Conclusion: This simple, yet not recognized explanation based on a literature search, is helpful to increase awareness of this analytical variable. It is also important to avoid misdiagnosis of FXI deficiency in patients with LA.

Development of an assay using a modified coagulation factor V to measure protein S activity

Unfolded Von Willebrand Factor Binds Protein S and Reduces Anticoagulant Activity

The natural anticoagulant protein S; hemostatic functions and deficiency

Proteome and Metabolome Profiling of Anticoagulant Disorders Induced by Familial Protein S Deficiency

Quantification of the contribution of individual coagulation factors to haemostasis using a microchip flow chamber system and reconstituted blood from deficient plasma

[Elucidation of an altered anticoagulant function due to Factor V abnormality and development of a simple screening assay for thrombophilia]

Plasma Coagulation Factor VII Activity and Its Correlates in Healthy Men

Comparison of several von Willebrand factor (VWF) activity assays for monitoring patients undergoing treatment with VWF/FVIII concentrates: improved performance with a new modified automated method.

Variability in combinations of APTT reagent and substrate plasma for a one‐stage clotting assay to measure factor VIII products

401 Detecting Hypofibrinolysis in Clinical Coagulation Testing

SARS-CoV-2 Vaccine Improved Hemostasis of a Patient with Protein S Deficiency: A Case Report

Total Plasma Protein S Is a Prothrombotic Marker in People Living With HIV

Measurement of extended half-life recombinant FVIII molecules: In vitro and ex vivo evidence of relevant assay discrepancies

Clot-Based Assay for Factor XI (FXI) Activity Is Highly Sensitive to Lupus Anticoagulant (LA) and Heparin with Potential Misdiagnosis of FXI Deficiency: The Importance of Recognizing Non-Parallelism

Analysis of PROS1 mutations and clinical characteristics in three Chinese families with hereditary protein S deficiency

Clinical Manifestation and Mutation Spectrum of 53 Unrelated Pedigrees with Protein S Deficiency in China.

Recurrent Pulmonary Embolism Associated with Deep Venous Thrombosis Diagnosed As Protein S Deficiency Owing to a Novel Mutation in PROS1

Insights from a Comprehensive Analysis of Pathogenic Variants and Their Impact on Coagulation Activity

Proposal for Objective Evaluation of the Performance of Various Functional APC-resistance Tests in Genotyped Patients

Assessment of activities or plasma levels of coagulation/anticoagulation factors in patients with venous thromboembolism

Plasma Levels of Protein S, Protein C, and Factor X: Effects of Sex, Hormonal State and Age